Clinical Trial Update: Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating bendamustine as a bridge to autologous or allogeneic transplant for relapsed/refractory lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-21